The most influential diabetes document in America just dropped. The American Diabetes Association’s 202 Standards of Care in Diabetes — published in December 2025 in Diabetes Care (Volume 49, Supplement 1) and now in effect across U.S. endocrinology practices — is the annual clinical playbook that 90%+ of American endocrinologists follow when treating Type 2 diabetes. The 2026 edition added new drugs, new tech, and new weight-loss language. It still treats diabetes as a chronic, progressive disease to be managed — not reversed.
What Just Happened
The ADA Standards of Care 2026 is a 400+ page document covering everything from screening and diagnosis to pharmacologic management, weight management, cardiovascular risk reduction, and complications. It’s the reference every endocrinologist, primary care physician, and diabetes educator in the country uses to make treatment decisions, as detailed in Medscape’s coverage of the 2026 release.
The headline changes for 2026, per the ADA Standards of Care and Medscape’s analysis:
- Pharmacologic approach for first-line therapy: Metformin is no longer the automatic default. The 2026 guidelines now recommend individualized first-line therapy based on comorbidities — GLP-1 receptor agonists or dual GIP/GLP-1 agonists for patients with cardiovascular disease, heart failure, or chronic kidney disease, per the ADA pharmacologic approaches section.
- Weight management emphasis: The 2026 edition gives weight management its own dedicated section with stronger language about the role of weight loss in diabetes care, including the use of FDA-approved anti-obesity medications alongside glucose-lowering therapy, as covered in Medscape’s analysis.
- Technology expansion: Continuous glucose monitoring (CGM) recommendations expanded to include more Type 2 patients on non-insulin therapy, per the ADA Standards of Care.
- Cardiovascular and kidney protection: Stronger recommendations for SGLT2 inhibitors and GLP-1 agonists in patients with established cardiovascular disease, heart failure, or chronic kidney disease regardless of A1c level, per the ADA pharmacologic approaches section.
The Question Nobody’s Asking
Here’s what every headline about the 2026 ADA Standards of Care is leaving out: the most influential diabetes document in America still treats diabetes as a chronic, progressive disease to be managed — not reversed.
The 2026 guidelines added more drugs, more tech, and more weight-loss language. But the underlying framework remains the same: add medications when A1c rises, escalate when A1c rises further, add more medications when complications develop. The word “reversal” appears nowhere in the document. The word “remission” appears in narrow, conditional contexts — never as a treatment goal. The patient is still on the conveyor belt. The conveyor belt just got faster.
That’s not a flaw. That’s the medical establishment’s consensus model — and it’s the model that 90%+ of
endocrinologists follow. Every drug added to the guidelines is a real win for patients who need medication. But
“better disease management” and “reversal of Type 2 diabetes” are two completely different games.
So the real question for the millions of Americans whose endocrinologists will follow these guidelines isn’t
“which new drug should I try?” It’s “why am I still diabetic in the first place, and what’s actually required to
reverse it?”
What Reversal Actually Looks Like
At Diabetes Reversal Group, we measure reversal by a single, unblinking standard: A1c 6.4% or lower — of
every diabetes medication — sustained. Not “controlled.” Not “managed.” Reversed.
Our patients hit reversal in an average of 5 months — the time to get the attached results, within the 4.5- month average from the independent study. The mechanism isn’t a molecule. It’s a system: a patented nutrition protocol (240 recipes, 7-day meal plans, telemedicine delivery, mobile app coaching) that reverses the underlying insulin resistance at the root. The world’s only patented protocol for Type 2 diabetes reversal (U.S. patent granted September 2020), validated by an independent study of 137 participants (2013–2021) showing an average post-program A1c of 6.04%, average time in program of 5 months, and a reversal rate of 26.28%.
You can read patient outcomes — A1cs before and after, medications discontinued, time to reversal — at
diabetesreversalgroup.com/testimonial/.
The Bottom Line
The ADA just rewrote its playbook. It added more drugs, more tech, and more weight-loss language. It still treats diabetes as a chronic, progressive disease to be managed — not reversed.
If you’re on metformin, a GLP-1, or insulin, and you’ve been told you’ll be on it for life, you owe it to yourself to
look at what’s actually possible. Watch our free webinar — the same presentation our medical team uses with
new patients. No pitch. Just the science, the data, and how to know if you’re a candidate.
By:
Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group
Kristine Burke, MD / Chief Medical Officer / Diabetes Reversal Group.